Status:
COMPLETED
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
There is great need for improved preoperative imaging in men with high-risk prostate cancer. Investigators propose to develop and validate an optimized simultaneous PET/MRI protocol for local, regiona...
Eligibility Criteria
Inclusion
- \- High-risk biopsy-proven treatment-naïve prostate adenocarcinoma (Gleason score ≥ 8 and/or serum PSA \> 20)
Exclusion
- Inability to tolerate or undergo PET/MRI
- Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)
- Recurrent prostate adenocarcinoma
- Known visceral, osseous, or extrapelvic metastases prior to fluciclovine-PET/MRI
- Known allergy to glucagon or gadolinium-based contrast
Key Trial Info
Start Date :
November 8 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03264456
Start Date
November 8 2017
End Date
February 13 2020
Last Update
March 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, United States, 35249